GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas

International Journal of Surgical Pathology

Volumn 23, Issue 6, 2015, Pages 447-453

  Abdou, Asmaa Gaber ^a   Eldien, Marwa Mohammad Serag ^a   Elsakka, Daliah ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

basal cell carcinoma; GLUT 1; squamous cell carcinoma

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; EGYPT; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN CARCINOMA; TUMOR DIFFERENTIATION; ADOLESCENT; BIOPSY; CHILD; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CHILD; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SKIN; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84938692804     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896915589968     Document Type: Article

References (26)

1. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB,. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003; 23: 7315-7328.
2. Gatenby RA, Gillies RJ,. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007; 39: 1358-1366.
3. Nelson, David L, Michael M,. Lehninger, Principles of Biochemistry. London, England: WH Freeman; 2008.
4. Hussein YR, Bandyopadhyay S, Semaan A,. Glut-1 expression correlates with basal-like breast cancer. Transl Oncol. 2011; 4: 321-327.
5. Havelund BM, Sørensen FB, Pløen J, Lindebjerg J, Spindler KL, Jakobsen A,. Immunohistological expression of HIF-1α GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer. APMIS. 2013; 121: 127-138.
6. Sadlecki P, Bodnar M, Grabiec M,. The role of hypoxia-inducible factor-1α glucose transporter-1 (GLUT-1), and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int. 2014; 2014:616850.
7. Semaan A, Munkarah AR, Arabi H,. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol. 2011; 121: 181-186.
8. North PE, Waner M, Mizeracki A, Mihm MC Jr., GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000; 31: 11-22.
9. Carvalho KC, Cunha IW, Rocha RM,. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo). 2011; 66: 965-972.
10. Huang XQ, Chen X, Xie XX,. Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7: 1651-1666.
11. Cho H, Lee YS, Kim J, Chung JY, Kim JH,. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 2013; 31: 607-615.
12. Jung JH, Im S, Jung ES, Kang CS,. Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer. Int J Med Sci. 2013; 10: 1217-1223.
13. Hussein MR,. Skin cancer in Egypt: a word in your ear. Cancer Biol Ther. 2005; 4: 593-595.
14. Baer SC, Casaubon L, Younes M,. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol. 1997; 37: 575-577.
15. Ayala FR, Rocha RM, Carvalho KC,. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules. 2010; 15: 2374-2387.
16. Abdou AG, Maraee AH, Eltahmoudy M, El-Aziz RA,. Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis. Am J Dermatopathol. 2013; 35: 731-737.
17. Macheda ML, Rogers S, Best JD,. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202: 654-662.
18. Yasuda M, Ogane N, Hayashi H,. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep. 2005; 14: 1499-1504.
19. Jans J, van Dijk JH, van Schelven S,. Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology. 2010; 75: 786-792.
20. Takanaga H, Frommer WB,. Facilitative plasma membrane transporters function during ER transit. FASEB J. 2010; 24: 2849-2858.
21. Tohma T, Okazumi S, Makino H,. Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005; 18: 185-189.
22. Demeda CF, Carvalho CH, Aquino AR, Nonaka CF, Souza LB, Pinto LP,. Expression of glucose transporters 1 and 3 in metastatic and non-metastatic lower lip squamous cell carcinoma. Braz Dent J. 2014; 25: 372-378.
23. Mendez LE, Manci N, Cantuaria G,. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol. 2002; 86: 138-143.
24. Pinheiro C, Sousa B, Albergaria A,. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol. 2011; 26: 1279-1286.
25. Youssef KK, Van Keymeulen A, Lapouge G,. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010; 12: 299-305.
26. Legan M, Tevžič S, Tolar A, Luzar B, Marolt VF,. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder. Pathol Oncol Res. 2011; 17: 61-66.